跨国制药企业在华发展战略

发布时间：2018-05-30 14:55

本文选题：跨国制药企业 + 发展战略　；参考：《东华大学》2014年硕士论文

【摘要】：制药产业一直对人类而言作为最核心的产业之一,其价值与意义为不得过高估计。随着中国对外国开放,政府政策对跨国投资者而言越来越有优势,跨国制药企业开始注意此潜力与机遇巨大的市场。跨国制药企业在中国发展可以跟踪到20世纪80年代。当时其开始冉冉地进入中国,熟悉市场,建立在华存在。该项研究探索跨国制药企业在华现状与面临的问题。目前,30多年发展历程以后,跨国制药企业获得中国药品市场的1／3,把中国作为战略性扩展的重点。因此,跨国制药企业获得许多中国提供给的优势,包括大的人才库,税收激励,成本降低,以及经受几个问题与挑战,例如,国家价格控制策略、复杂的分配系统与假冒的药品。研究集中跨国制药企业在华现状的详细信息,并比较一些核心数据来表示跨国制药企业在中国发展的绩效。另外,研究概要并详细的议论这些企业面临的问题与它们导致的影响。该项研究的重点为跨国制药企业在华发展历程当中的战略调整,最核心的问题为跨国制药企业在华发展过程中选择怎样的方法,如何保持不断的上升,中国的对这些企业的角色如何变成。研究过程当中全球10大制药企业作为样本。研究结果提议,跨国制药企业在华发展分为三个主要阶段,初期(1979年——1992年),中期(1992年一2002年)与后期(2002年至今)。研究的目的之一为发现每个阶段当中企业发展的特征,归纳跨国制药企业在华发展步骤与、精选的方式。除此之外,研究提供给数据来显示跨国制药企业不仅一直扩展中国市场、重视中国若重要的生产与研发基地,而且证明作为样本的全球10大制药企业在华进行的战略试有效的。此论文得出一些战略性特征、步骤与趋势,希望助于制药产业的企业从全球十大企业的建立获得有效的建议与理念。
[Abstract]:Pharmaceutical industry has always been one of the core industries for human beings, its value and significance must not be overestimated. As China opens up to foreign countries and government policies become more and more advantageous for multinational investors, multinational pharmaceutical companies are beginning to pay attention to this potential and huge market opportunities. The development of multinational pharmaceutical enterprises in China can be traced to the 1980 s. At that time, it began to slowly enter China, familiar with the market and establish a presence in China. This study explores the current situation and problems faced by multinational pharmaceutical enterprises in China. After more than 30 years of development, multinational pharmaceutical enterprises have gained a third of China's drug market, and regard China as the focus of strategic expansion. As a result, multinational pharmaceutical companies gain many of the advantages that China offers, including a large pool of talent, tax incentives, lower costs, and several problems and challenges, such as national price control strategies. Complex distribution systems with counterfeit drugs. This paper focuses on the detailed information of multinational pharmaceutical enterprises in China and compares some core data to show the performance of multinational pharmaceutical enterprises in China. In addition, the study outlines and discusses in detail the problems faced by these companies and their implications. The focus of this study is on the strategic adjustment of multinational pharmaceutical enterprises in the development process in China. The most important question is what methods to choose and how to keep increasing in the process of development of multinational pharmaceutical enterprises in China. How China's role towards these companies has become. During the research process, the world's 10 largest pharmaceutical companies as a sample. The results suggest that the development of multinational pharmaceutical enterprises in China can be divided into three main stages: the initial stage (1979-1992), the middle stage (1992-2002) and the later period (2002-present). One of the purposes of the study is to find out the characteristics of enterprise development in each stage, and to sum up the development steps and methods of multinational pharmaceutical enterprises in China. In addition, the study provides data to show that multinational pharmaceutical companies not only have been expanding the Chinese market, attach importance to China's important production and research and development base, but also prove that the strategic trial conducted by the 10 largest pharmaceutical companies in the world as a sample is effective in China. This paper obtains some strategic features, steps and trends, hoping to help pharmaceutical industry enterprises to obtain effective suggestions and ideas from the establishment of ten enterprises in the world.
【学位授予单位】：东华大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：F272;F416.72

【参考文献】